MMP2 and varicose ulcer: After 12 weeks of treatment, 23% of the test group (n = 13) and 18% of the placebo group (n = 11) achieved complete wound healing and there was a potential reduction in patients’ complaints of pain, with up to 85% reduction in pain among patients with lesions.15 LILT promotes increased angiogenesis by increasing expression of hypoxia inducible factor alpha (HIF-α) and vascular endothelial growth factor (VEGF) while also reducing activity of cellular matrix metalloproteinase-2 (MMP-2) in vitro,23 and possible improvement of complaints of pain related to venous ulcers.18